The American Thoracic Society/European Respiratory Society jointly created a Task Force
on “Outcomes for COPD pharmacological trials: from lung function to biomarkers” to inform …

▪ Abstract As many more clinical trials collect economic information within their study design,
so health economics analysts are increasingly working with patient-level data on both costs …

Importance Optimal use of whole-exome sequencing (WES) in the pediatric setting requires
an understanding of who should be considered for testing and when it should be performed …

Background Severe acute respiratory failure in adults causes high mortality despite
improvements in ventilation techniques and other treatments (eg, steroids, prone …

Purpose: Implementation of novel genetic diagnostic tests is generally driven by
technological advances because they promise shorter turnaround times and/or higher …

Background There are a lack of reliable data on the epidemiology and associated burden
and costs of asthma. We sought to provide the first UK-wide estimates of the epidemiology …

Background The National Lung Screening Trial (NLST) showed that screening with low-
dose computed tomography (CT) as compared with chest radiography reduced lung-cancer …

In trial‐based cost‐effectiveness analysis baseline mean utility values are invariably
imbalanced between treatment arms. A patient's baseline utility is likely to be highly …

Several guidelines on cost-effectiveness analysis (CEA) already exist. There are two
reasons for producing another set. The first is that traditional or, incremental, CEA ignores …

Purpose: To undertake the first prospective cost-effectiveness study of whole-exome
sequencing (WES) as an early, routine clinical test for infants with suspected monogenic …